Medesis Pharma is a clinical development stage biopharmaceutical Company that is engaged through its unique and proven drug delivery technology – Aonys® – in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address major unmet medical needs.
Medesis Pharma is currently applying its Aonys® technology for:
Two drug candidates on major markets for neurodegenerative diseases: Alzheimer’s and Huntington’s .
Two drug candidates from R&D programs for antiviral treatments redirected to respond to the health emergency and treat COVID-19 at various stages: one for patients hospitalized with acute respiratory distress, and another for early-stage treatment at general practice level.
Two drug candidates for treating people contaminated following a civil or military nuclear accident: Plutonium decorporation and Cesium decorporation.
Medesis Pharma’s technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue), as well as a collaborative program with the company TRANSGENE.
.
Hippocrate
NanosiRNA® COVID-19: specific antiviral treatment Medesis Pharma has a microemulsion technology that enables it to deliver these non-modified native siRNAs directly into the cytoplasm of all the organism’s cells via the HDL lipoprotein receptors, crossing the blood–brain barrier (BBB) after a non-invasive oral administration.
Medesis Pharma is developing a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 – NanoManganese®). Preclinical trials have been carried out with the French Armed Forces Biomedical Research Institute (IRBA). (Study reports available) A series of studies have been
TRANSGENE (Euronext Paris: TNG), a biotechnology company designing and developing virus-based immunotherapies against cancers and infectious diseases, has signed a collaborative research agreement with Medesis Pharma with exclusive license options to co-develop an intracellular protein inhibitor that decreases the efficacy
Text currently
